Free tool
FAERS Monitor: Zyprexa Relprevv
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022173 or its brand name (Zyprexa Relprevv, Olanzapine Pamoate). Reports on generic versions are filed under their own applications.
Reports
40,828
Serious
31,555
77% of reports
Hospitalization
15,660
Death reported
4,498
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diabetes mellitus4,878
- weight increased4,144
- drug ineffective1,953
- off label use1,900
- pancreatitis1,734
- hypertension1,688
- type 2 diabetes mellitus1,639
- anxiety1,571
- nausea1,466
- somnolence1,410
- fatigue1,388
- insomnia1,351
- overdose1,333
- depression1,288
- suicide attempt1,277
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,651 |
| 2005 | 2,497 |
| 2006 | 3,074 |
| 2007 | 2,993 |
| 2008 | 1,331 |
| 2009 | 2,936 |
| 2010 | 2,552 |
| 2011 | 2,496 |
| 2012 | 1,837 |
| 2013 | 1,224 |
| 2014 | 1,275 |
| 2015 | 5,915 |
| 2016 | 1,368 |
| 2017 | 1,532 |
| 2018 | 1,381 |
| 2019 | 1,372 |
| 2020 | 1,176 |
| 2021 | 936 |
| 2022 | 960 |
| 2023 | 790 |
| 2024 | 580 |
| 2025 | 583 |
| 2026 | 368 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,013,331 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| diabetes mellitusSignal | 4,878 | 35.1 | 34.2 | 151,999 |
| type 2 diabetes mellitusSignal | 1,639 | 26.3 | 25.1 | 38,005 |
| pancreatitisSignal | 1,734 | 17.4 | 16.6 | 26,045 |
| suicide attemptSignal | 1,277 | 11.1 | 10.5 | 11,464 |
| weight increasedSignal | 4,144 | 9.7 | 9.4 | 32,045 |
| hypertensionSignal | 1,688 | 4.1 | 3.9 | 4,011 |
| somnolenceSignal | 1,410 | 3.6 | 3.4 | 2,686 |
| overdoseSignal | 1,333 | 3.2 | 3.0 | 2,019 |
| depressionSignal | 1,288 | 2.9 | 2.8 | 1,641 |
| anxietySignal | 1,571 | 2.9 | 2.7 | 1,906 |
| insomniaSignal | 1,351 | 2.6 | 2.5 | 1,364 |
| off label use | 1,900 | 1.1 | 1.1 | 25 |
| nausea | 1,466 | 1.0 | 0.9 | 3 |
| fatigue | 1,388 | 0.9 | 0.9 | 10 |
| drug ineffective | 1,953 | 0.8 | 0.7 | 153 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.